You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / AJANTA PHARMA

AJANTA PHARMA
Intrinsic Value | Fundamental Analysis

Returns | 1W : -6.6% , 1M : 0.6%,1Y : 23.5%
www.ajantapharma.com
BOM : 532331     NSE : AJANTPHARM    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward
Pledged Shares : None or < 25%
Jan 24,2022
Price(EOD): Rs. 2,135.40
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Affiliate Link.
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
AJANTA PHARMA -6.6% 0.6% 23.5%
SUN PHARMACEUTICAL INDUSTRIES -5.4% 1.9% 35.7%
DIVIS LABORATORIES -10.7% -9.1% 14.7%
DR REDDYS LABORATORIES -7% -6% -13.6%
CIPLA -1.2% -1.8% 5.4%
GLAND PHARMA -10.1% -15.1% 56%
PIRAMAL ENTERPRISES -8% -8.2% 58.9%
CADILA HEALTHCARE -6% -12.5% -15.5%
TORRENT PHARMACEUTICALS -2.5% 2% 14.9%


FUNDAMENTAL ANALYSIS OF AJANTA PHARMA

 
Fundamentals Score
[ Q(TTM): Sep2021, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]
Show Me the Stocks with Fundamentals better than AJANTA PHARMA Plus/Pro


VALUATION OF AJANTA PHARMA

 
Valuation Score
[As on : Jan 24,2022 ]

Ratio Consolidated
P/E
P/B
P/S
28.25
P/E Calculated based on EPS of 75.59
[ Mar2021 - Consolidated Results ]

6.17
P/B Calculated based on Book Value of 346.24
[ Mar2021 - Consolidated Results ]

5.89
P/S Calculated based on Revenues of 3138.37 Cr
[ TTM - Consolidated Results ]

Show Me the Stocks with Valuation better than AJANTA PHARMA Plus/Pro


FAIR VALUE OF AJANTA PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
78%
107%
120%

SHARE PRICE MOMENTUM OF AJANTA PHARMA

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2021
2020
2019
Avg_3yrs
0
0
0
-
0
0.02
0.02
0.01
[Last Annual Data : Mar2021]

PLEDGED SHARES

Pledged Shares
15.37 %
As on : Dec2021

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
18.29%
19.35%
18.13%
12.77%
23.59%
-4.17%
4.49%
15.11%
QtrlyTrend
6
Latest Qtr: Sep2021

AJANTA PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE LARGE MIDCAP -6.6% -0.2% 21.9%
S&P BSE 200 -6.6% -0.2% 22.6%
S&P BSE 250 LARGEMIDCAP -6.6% -0.3% 23.3%
S&P BSE 500 -6.8% -0.2% 24.9%
S&P BSE ALLCAP -6.8% -0.1% 26.1%
S&P BSE HEALTHCARE -6.8% -5.1% 10.7%
S&P BSE 150 MIDCAP -7.7% -1.4% 38.3%
S&P BSE 400 MIDSMALLCAP -7.9% -0.7% 42.3%
S&P BSE MIDSMALLCAP -8.1% -1% 43%
S&P BSE MID CAP -8.2% -2.6% 29.6%
NSE Indices1W1M1Y
NIFTY MIDCAP150 QUALITY 50 -3.7% 2.3% NA
NIFTY 200 -6.7% -0.3% 22.5%
NIFTY 500 -6.8% -0.3% 24.9%
NIFTY LARGE MIDCAP 250 -7.1% -1% 28.9%
NIFTY500 MULTICAP 50:25:25 -7.2% -0.3% 33%
NIFTY MIDCAP150 -7.9% -1.9% 37.5%
NIFTY MID SMALL400 -8% -1% 42.6%
NIFTY FREE MIDCAP 100 -8.3% -1.8% 36.9%

You may also like the below Video Courses


FAQ [Frequently Asked Questions]


Is AJANTA PHARMA good for long term investment?

As on 24-Jan-2022, the Fundamentals of AJANTA PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of AJANTA PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is AJANTA PHARMA UnderValued or OverValued?

As on 24-Jan-2022, AJANTA PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of AJANTA PHARMA ?

As on 24-Jan-2022, the Intrinsic Value of AJANTA PHARMA is Rs. 1,031.73 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 1,201.61
Fair Value [Median EV / Sales Model] : Rs. 1,031.73
Fair Value [Median Price / Sales Model] : Rs. 969.77
Median Fair Value of AJANTA PHARMA : Rs. 1,031.73

Is AJANTA PHARMA trading at a Premium or Discount?

As on 24-Jan-2022, AJANTA PHARMA is trading at a Premium of 107% based on the estimates of Median Intrinsic Value!

What is the Financial Performance of Industry Peers of AJANTA PHARMA ?

Check out Annual Financials of Industry Peers
Share Price & Financials of SUN PHARMACEUTICAL INDUSTRIES LTD | BOM: 524715 | NSE: SUNPHARMA
Share Price & Financials of DIVIS LABORATORIES LTD | BOM: 532488 | NSE: DIVISLAB
Share Price & Financials of DR REDDYS LABORATORIES LTD | BOM: 500124 | NSE: DRREDDY
Share Price & Financials of CIPLA LTD | BOM: 500087 | NSE: CIPLA
Share Price & Financials of GLAND PHARMA LTD | BOM: 543245 | NSE: GLAND
Check out Quarterly Results of Industry Peers
Quarterly Results of SUN PHARMACEUTICAL INDUSTRIES LTD
Quarterly Results of DIVIS LABORATORIES LTD
Quarterly Results of DR REDDYS LABORATORIES LTD
Quarterly Results of CIPLA LTD
Quarterly Results of GLAND PHARMA LTD

What are the Frequent Comparisons in this Industry?

Compare Analytics
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
Browse Market Cap of Industry Peers
Market Cap of SUN PHARMACEUTICAL INDUSTRIES LTD
Market Cap of DIVIS LABORATORIES LTD
Market Cap of DR REDDYS LABORATORIES LTD
Market Cap of CIPLA LTD
Market Cap of GLAND PHARMA LTD

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z